← Leaderboards
Sean T. Zuckerman
Affinity Therapeutics, Llc
$626,752
Attributed
$626,752
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $225K · FY2014–17$250K$187.5K$125K$62.5K$0
'14
'15
'16
'17
Funding mix
By agency
NIH$626,752 · 2
By mechanism
R43$626,752 · 2
Top collaborators
No co-investigators on record.
Most similar at Affinity Therapeutics, Llc
Same institution · by research overlap
- Julius N. Korley$2,005,551
Others in their field
Top investigators on “Hyperplasia”
- Devendra K. Agrawal · Creighton University$23,515,446
- Scott W Wong · Oregon Health And Science University$21,099,510
- Frank W Logerfo · Beth Israel Deaconess Medical Center$21,014,586
- Kenneth M Kaye · Brigham And Women'S Hospital$17,592,088
- Shou-Jiang Gao · University Of Texas Hlth Science Center$16,034,253
- Jae U Jung · Cleveland Clinic Lerner Com-Cwru$15,743,600
Research focus
HyperplasiaIn Vivo ModelFundingHistologyInnovationIn VivoDoseFamily SuidaeGenerationsHemodialysisIncubatorsAngioplastyBlood VesselsAffinityDosageCaliberDrug Delivery SystemsEnd Stage Renal FailureCell ProliferationFutureArteriovenous FistulaCostBaseNovel Strategies
Grant awards (4)
Localized Statin Delivery for Prevention of Primary AV Fistula Failure$225,000
R43 · FY2017 · HL · contact PI
Affinity-based delivery of Sirolimus for prevention of AV graft failure$176,753
R43 · FY2015 · HL · contact PI
Affinity-based delivery of Sirolimus for prevention of AV graft failure$199,999
R43 · FY2014 · HL · contact PI
Affinity-based delivery of Sirolimus for prevention of AV graft failure$25,000
R43 · FY2014 · HL · contact PI